title: Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation--durable complete remission following imatinib therapy.
authors.forename: I H
authors.initials: IH
authors.lastname: Dufva
authors.forename: H
authors.initials: H
authors.lastname: Karle
authors.forename: K
authors.initials: K
authors.lastname: Brondum-Nielsen
authors.forename: M K
authors.initials: MK
authors.lastname: Andersen
authors.forename: H O
authors.initials: HO
authors.lastname: Madsen
authors.forename: H E
authors.initials: HE
authors.lastname: Johnsen
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D002899:Chromosomes, Human, Pair 9; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D007964:Leukocytosis / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012074:Remission Induction; D013601:T-Lymphocytes / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl